Want to see PHBI full AI Analyst Report?
PHBI Stock Chart & Stats
<$0.01
$0.00(0.00%)
At close: 4:00 PM EST
<$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.03
Previous CloseN/A
Volume191.24K
Average Volume (3M)N/A
Market Cap
$622.21K
Enterprise Value$722.72K
Total Cash (Recent Filing)$721.00
Total Debt (Recent Filing)$355.59K
Price to Earnings (P/E)―
Beta0.96
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding691,345,760
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.25
Price to Sales (P/S)277.91
P/FCF Ratio-28.48
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue302.65
Enterprise Value/Gross Profit-1.81K
Enterprise Value/Ebitda1.66
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Industry PositionOperating in the specialty and generic drug segment implies structurally resilient demand and regulatory barriers that can support pricing power and recurring revenue. Over months, entrenched product niches and regulatory complexity can sustain differentiated margins if product execution follows.
Strong Revenue Growth TrendAn extremely large reported revenue growth rate indicates rapid top-line acceleration from a tiny base, signaling early commercial traction or successful pilot sales. If the company can scale these initial sales and stabilize operations, this trend can translate into durable revenue expansion over 2–6 months.
Reduced Operating Cash BurnMaterial improvement in operating cash outflow demonstrates tighter cost control and improved operational efficiency. A sustained reduction in cash burn enhances runway and lowers near-term financing pressure, improving the company’s ability to invest in commercialization or R&D over the medium term.
Bears Say
Stressed Balance SheetDeeply negative equity and meaningful debt versus a tiny asset base indicate severe solvency and financial flexibility constraints. Over months this restricts the company’s ability to fund operations, negotiate supplier terms, or invest in product development without dilutive or costly external financing.
Consistent Negative Operating Cash FlowPersistent negative operating and free cash flow means core operations do not generate self-sustaining liquidity. This structural cash deficit forces reliance on external capital, which can be scarce or expensive and undermines the company’s capacity to fund ongoing R&D or scale manufacturing sustainably.
Tiny, Unstable Revenue And Non‑operating EarningsRevenue scale is negligible and core operating profitability is deeply negative, with reported net income driven by non-operating items. This indicates weak unit economics and that current earnings are not durable, leaving margins and growth highly vulnerable absent genuine core business improvement.
PHBI FAQ
What was Pharmagreen Biotech Inc.’s price range in the past 12 months?
Pharmagreen Biotech Inc. lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.
What is Pharmagreen Biotech Inc.’s market cap?
Pharmagreen Biotech Inc.’s market cap is $622.21K.
When is Pharmagreen Biotech Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Pharmagreen Biotech Inc.’s earnings last quarter?
Currently, no data Available
Is Pharmagreen Biotech Inc. overvalued?
According to Wall Street analysts Pharmagreen Biotech Inc.’s price is currently Overvalued.
Does Pharmagreen Biotech Inc. pay dividends?
Pharmagreen Biotech Inc. does not currently pay dividends.
What is Pharmagreen Biotech Inc.’s EPS estimate?
Pharmagreen Biotech Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmagreen Biotech Inc. have?
Pharmagreen Biotech Inc. has 691,345,760 shares outstanding.
What happened to Pharmagreen Biotech Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pharmagreen Biotech Inc.?
Currently, no hedge funds are holding shares in PHBI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharmagreen Biotech Inc.
Pharmagreen Biotech Inc. is a biotechnology solutions provider primarily engaged in cultivating young plant stock for the medical cannabis and CBD hemp industries. Established in 2007, the company operates from its base in Coquitlam, Canada.